Overview
- Third-quarter profit reached about £2 billion on revenue of £8.5 billion, led by a 16% rise in specialty medicines with HIV and oncology as key drivers.
- Full-year 2025 outlook now calls for revenue growth of 6%–7%, core operating profit up 9%–11%, and core EPS up 10%–12%.
- Management said the outlook already reflects tariffs enacted to date and a modeled 15% European impact, with mitigation options identified.
- GSK is pursuing a five-year, $30 billion U.S. investment program as it navigates the White House tariff push on imported branded drugs.
- Shares jumped, reaching their highest in over a year in some trading, while U.S. vaccine sales were a weak spot with a reported 15% drop for Shingrix in the U.S.